Palvella Therapeutics (PVLA) announced that the United States Patent and Trademark Office, USPTO, issued patent No. 12,329,748 for claims related to the Company’s lead product candidate QTORIN 3.9% rapamycin anhydrous gel. The patent provides broad protection for the proprietary anhydrous topical composition and methods of use for QTORIN rapamycin. “Our sixth issued U.S. patent marks another meaningful milestone in solidifying the exclusivity position of QTORIN(TM) rapamycin,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “We’re executing a multi-layered strategy to protect and maximize the long-term value of QTORIN rapamycin-anchored by strong intellectual property, proprietary formulation and manufacturing trade secrets, and regulatory exclusivities.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics Holds Annual Stockholders Meeting
- Palvella Therapeutics receives initial proceeds from FDA Orphan Products grant
- Palvella Therapeutics Advances in Rare Skin Disease Therapies
- Palvella Therapeutics appoints Kline as Chief Commercial Officer
- Promising Outlook for Palvella Therapeutics: Buy Rating Affirmed by Andrew Fein Due to Phase 3 SELVA Trial Success and Strategic Market Position